Boston Trust Walden Corp Lowers Holdings in Zoetis Inc. (NYSE:ZTS)

Boston Trust Walden Corp lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.4% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 42,959 shares of the company’s stock after selling 604 shares during the period. Boston Trust Walden Corp’s holdings in Zoetis were worth $8,393,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Webster Bank N. A. raised its position in Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after acquiring an additional 82 shares in the last quarter. Quarry LP increased its holdings in shares of Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares in the last quarter. LRI Investments LLC purchased a new position in shares of Zoetis during the 1st quarter valued at approximately $43,000. Central Valley Advisors LLC acquired a new position in shares of Zoetis in the 2nd quarter valued at $49,000. Finally, EdgeRock Capital LLC purchased a new stake in Zoetis during the second quarter worth $56,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ZTS shares. BTIG Research lifted their price objective on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Piper Sandler lifted their price target on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. JPMorgan Chase & Co. increased their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Stifel Nicolaus boosted their price objective on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Finally, Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $221.44.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $180.01 on Friday. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The firm has a market capitalization of $82.14 billion, a PE ratio of 34.68, a P/E/G ratio of 2.94 and a beta of 0.89. The business’s 50 day moving average price is $189.10 and its 200-day moving average price is $177.79.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.07. The company had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.41 EPS. As a group, equities research analysts expect that Zoetis Inc. will post 5.83 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.96%. Zoetis’s payout ratio is 33.14%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.